It Seems Iovance Biotherapeutics Incorporated (NASDAQ:IOVA) Will Go Down. Just Reported More Shorted Shares

February 14, 2018 - By sdfsdfsdf

 It Seems Iovance Biotherapeutics Incorporated (NASDAQ:IOVA) Will Go Down. Just Reported More Shorted Shares

The stock of Iovance Biotherapeutics Incorporated (NASDAQ:IOVA) registered an increase of 31.31% in short interest. IOVA’s total short interest was 3.11 million shares in February as published by FINRA. Its up 31.31% from 2.37M shares, reported previously. With 402,000 shares average volume, it will take short sellers 8 days to cover their IOVA’s short positions.

It closed at $16.65 lastly. It is down 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.45 billion. The companyÂ’s lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patientsÂ’ tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

More notable recent Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news were published by: Seekingalpha.com which released: “Iovance adds to rally, up 12%” on January 19, 2018, also Nasdaq.com with their article: “Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher” published on January 30, 2018, Seekingalpha.com published: “Biotech Forum Daily Digest For January 31st” on January 31, 2018. More interesting news about Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were released by: Globenewswire.com and their article: “Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock” published on January 24, 2018 as well as Globenewswire.com‘s news article titled: “Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock …” with publication date: January 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.